TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00135083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: * Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: * Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: * Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below.
Study: NCT01908010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-354
Description: ABT-354 Low Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-354
Description: ABT-354 High Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02081586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: Smartphone app developed to assist patients practice CBT skills throughout the week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: Smartphone app developed to assist patients practice CBT skills throughout the week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: Smartphone app developed to assist patients practice CBT skills throughout the week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Diabetes Care at PCP
Description: Patients receive ADA standard of Care with physician at PCP office

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Diabetes Care at PCP
Description: Patients receive ADA standard of Care with physician at PCP office

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Diabetes Care at PCP
Description: Patients receive ADA standard of Care with physician at PCP office

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Care at PCP
Description: Patients receive ADA standard of Care with physician at PCP office
Study: NCT02460276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT04146155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide+standard-of-care treatment
Description: Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.~Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies in accordance with local clinical practice guidelines.
Study: NCT00636064

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parecoxib Sodium/Valdecoxib
Description: Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/Valdecoxib
Description: Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Placebo
Description: Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Study: NCT03399370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran Sodium
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study: NCT04088032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib, durvalumab and aromatase inhibitor
Description: Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
Study: NCT03691922

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane (ESP) Block
Description: 1. Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~2. PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periarticular Infiltration (PAI)
Description: 1. Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~2. PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle
Study: NCT04144426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified diet
Description: Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
Study: NCT03508310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking Care of Me Video
Description: The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
Study: NCT01015404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin
Description: Administered to the bone defect during flap operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin
Description: Administered to the bone defect during flap operation
Study: NCT00695071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: Oral
Study: NCT01371968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfentanil
Description: Alfentanil is administered intravenously at the end of surgery.
Study: NCT02249988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX203 therapeutic Hepatitis B vaccine treatment arm
Study: NCT03601910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D308 10mg Tab.
Description: D308 10mg Tab.1T single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D308 10mg Tab.
Description: D308 10mg Tab.1T single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-380 10mg Tab.
Description: CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-380 10mg Tab.
Description: CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
Study: NCT04777968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
Study: NCT01202955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone
Description: Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
Study: NCT04518748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90
Description: Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy
Description: SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 3-5 fractions over 1-2 weeks, after Y-90 SIRT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Within 3 hours of completing Y-90 SIRT
Study: NCT04146155

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard-of-care treatment
Description: Standard-of-care treatment including: metformin should be given as the first line therapy as long as it is tolerated and not contraindicated; other agents, including sulfonylureas or glucosidase inhibitor or insulin, should be added to metformin .Glycemic control will be managed by the investigators in accordance with local clinical practice guidelines by the adjustment of concomitant glucose-lowering agents or the addition of new antidiabetic medications with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
Study: NCT04518748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therasphere
Description: Glass microspheres containing Y-90, administered at day 0 by SIRT
Study: NCT03614611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contiform pessary
Description: Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)
Study: NCT00158028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo match in identical tablets
Study: NCT03934658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare Therapeutic System
Description: A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NightWare Therapeutic System in Sham Mode
Description: A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
Study: NCT04655131

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein isolate
Description: Commercially available, FDA approved whey protein isolate for dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: Commercially available, FDA approved whey protein isolate for dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: Commercially available, FDA approved whey protein isolate for dietary supplementation
Study: NCT03454542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menicon Modified Lens Design
Description: Randomized in a daily wear, single day (6 hours or more) evaluation
Study: NCT01803061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebCan
Description: Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
Study: NCT02533284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupevecaine
Description: US guided TAP using Bupevecaine 0.25 %

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupevecaine
Description: US guided TAP using Bupevecaine 0.25 %

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: US guided TAP using placebo (saline)
Study: NCT02087735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry extract
Description: The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry extract
Description: The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry extract
Description: The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
Study: NCT01481597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deuteporfin
Description: deuteporfin 1 mg/kg IV as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deuteporfin
Description: deuteporfin 2.5 mg/kg IV as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deuteporfin
Description: deuteporfin 5 mg/kg IV as a single dose
Study: NCT01494441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/BCP
Description: The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/BCP/TSRH® Spinal System
Description: rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
Study: NCT01481597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deuteporfin
Description: deuteporfin 7.5 mg/kg IV as a single dose
Study: NCT01494441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft/TSRH® Spinal System
Description: The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
Study: NCT03940482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating As Treatment (TREAT) for Diabetes.
Description: Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
Study: NCT01481597

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
Study: NCT01551992

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quill suture vs. Interrupted suture
Description: To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quill suture vs. Interrupted suture
Description: To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
Study: NCT03737942

Intervention type: DEVICE
Intervention: monitoring of neuromuscular function
Description: started by percutaneous stimulation of the cubital nerve at the wrist level

Intervention type: DEVICE
Intervention: monitoring of neuromuscular function
Description: started by percutaneous stimulation of the cubital nerve at the wrist level

Intervention type: DEVICE
Intervention: monitoring of neuromuscular function
Description: started by percutaneous stimulation of the cubital nerve at the wrist level